ArticleNPJ Parkinson's disease2017

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.

Howard E Gendelman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.